These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10569498)

  • 1. Cost of inactivated vs. oral poliovirus vaccine.
    Dreazen JR
    Am Fam Physician; 1999 Nov; 60(7):1929, 1932. PubMed ID: 10569498
    [No Abstract]   [Full Text] [Related]  

  • 2. The new immunization debate.
    Adler P
    Pediatrics; 1996 Oct; 98(4 Pt 1):795-6. PubMed ID: 8885968
    [No Abstract]   [Full Text] [Related]  

  • 3. The new immunization debate.
    Schneider S
    Pediatrics; 1996 Oct; 98(4 Pt 1):795; author reply 796. PubMed ID: 8885967
    [No Abstract]   [Full Text] [Related]  

  • 4. The new immunization debate.
    Terry WF
    Pediatrics; 1996 Oct; 98(4 Pt 1):795; author reply 796. PubMed ID: 8885966
    [No Abstract]   [Full Text] [Related]  

  • 5. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polio eradication: the endgame.
    Nat Med; 2001 Feb; 7(2):131. PubMed ID: 11175817
    [No Abstract]   [Full Text] [Related]  

  • 8. Polio eradication. Rethinking the polio endgame.
    Roberts L
    Science; 2009 Feb; 323(5915):705. PubMed ID: 19197036
    [No Abstract]   [Full Text] [Related]  

  • 9. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polio eradication in India: how far are we from reaching the goal?
    Banerjee K; Sahu S; Bandyopadhyay S
    Indian J Pediatr; 2001 Mar; 68 Suppl 1():S6-14. PubMed ID: 11411387
    [No Abstract]   [Full Text] [Related]  

  • 11. AAFP childhood immunization update. AAFP Commission on Clinical Policies and Research.
    Am Fam Physician; 1998 Jan; 57(1):158. PubMed ID: 9447221
    [No Abstract]   [Full Text] [Related]  

  • 12. Polio immunization policy in Mexico: economic assessment of current practice and future alternatives.
    Mascareñas A; Salinas J; Tasset-Tisseau A; Mascareñas C; Khan MM
    Public Health; 2005 Jun; 119(6):542-9. PubMed ID: 15826896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on immunization with inactivated and liver poliovirus vaccines.
    Böttiger M
    Acta Paediatr Scand; 1966; ():Suppl 164:1-42. PubMed ID: 5326196
    [No Abstract]   [Full Text] [Related]  

  • 14. Monitoring vaccines for human oncogenicity--discussion.
    Robbins FC
    Natl Cancer Inst Monogr; 1968 Dec; 29():457-8. PubMed ID: 4305437
    [No Abstract]   [Full Text] [Related]  

  • 15. Time for changes in immunization: inactivated poliovirus vaccine and a family practice immunization book.
    Zimmerman RK
    J Fam Pract; 1999 Aug; 48(8):588-9. PubMed ID: 10496636
    [No Abstract]   [Full Text] [Related]  

  • 16. The costs of future polio risk management policies.
    Tebbens RJ; Sangrujee N; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral polio vaccines and their role in polio eradication in India.
    Paul Y
    Expert Rev Vaccines; 2009 Jan; 8(1):35-41. PubMed ID: 19093771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral polio vaccine and human cancer: a reassessment of SV40 as a contaminant based upon legal documents.
    Kops SP
    Anticancer Res; 2000; 20(6C):4745-9. PubMed ID: 11205211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
    Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.